Insider Selling: Eli Lilly And Co (LLY) Major Shareholder Sells 15,500 Shares of Stock

Eli Lilly And Co (NYSE:LLY) major shareholder Lilly Endowment Inc sold 15,500 shares of the firm’s stock in a transaction dated Tuesday, December 4th. The shares were sold at an average price of $119.00, for a total value of $1,844,500.00. Following the completion of the sale, the insider now directly owns 118,015,304 shares in the company, valued at $14,043,821,176. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Lilly Endowment Inc also recently made the following trade(s):

  • On Wednesday, November 28th, Lilly Endowment Inc sold 190,000 shares of Eli Lilly And Co stock. The shares were sold at an average price of $115.57, for a total value of $21,958,300.00.
  • On Monday, November 19th, Lilly Endowment Inc sold 195,000 shares of Eli Lilly And Co stock. The shares were sold at an average price of $115.31, for a total value of $22,485,450.00.
  • On Friday, November 16th, Lilly Endowment Inc sold 200,000 shares of Eli Lilly And Co stock. The shares were sold at an average price of $113.74, for a total value of $22,748,000.00.
  • On Monday, November 12th, Lilly Endowment Inc sold 202,540 shares of Eli Lilly And Co stock. The shares were sold at an average price of $113.48, for a total value of $22,984,239.20.
  • On Wednesday, October 17th, Lilly Endowment Inc sold 174,696 shares of Eli Lilly And Co stock. The shares were sold at an average price of $113.25, for a total value of $19,784,322.00.
  • On Monday, October 8th, Lilly Endowment Inc sold 14,632 shares of Eli Lilly And Co stock. The shares were sold at an average price of $115.91, for a total value of $1,695,995.12.
  • On Wednesday, October 3rd, Lilly Endowment Inc sold 78,962 shares of Eli Lilly And Co stock. The shares were sold at an average price of $109.01, for a total value of $8,607,647.62.
  • On Thursday, September 27th, Lilly Endowment Inc sold 92,447 shares of Eli Lilly And Co stock. The shares were sold at an average price of $107.00, for a total value of $9,891,829.00.
  • On Tuesday, September 25th, Lilly Endowment Inc sold 55,590 shares of Eli Lilly And Co stock. The shares were sold at an average price of $106.41, for a total value of $5,915,331.90.
  • On Friday, September 7th, Lilly Endowment Inc sold 180,000 shares of Eli Lilly And Co stock. The stock was sold at an average price of $106.76, for a total value of $19,216,800.00.

LLY traded down $2.43 during midday trading on Friday, reaching $113.41. 1,135,759 shares of the company’s stock were exchanged, compared to its average volume of 4,162,691. The stock has a market cap of $123.43 billion, a price-to-earnings ratio of 26.50, a P/E/G ratio of 1.82 and a beta of 0.31. The company has a quick ratio of 1.53, a current ratio of 1.91 and a debt-to-equity ratio of 0.83. Eli Lilly And Co has a one year low of $73.69 and a one year high of $119.84.

Eli Lilly And Co (NYSE:LLY) last announced its quarterly earnings results on Tuesday, November 6th. The company reported $1.39 EPS for the quarter, topping analysts’ consensus estimates of $1.35 by $0.04. The firm had revenue of $6.06 billion during the quarter, compared to analysts’ expectations of $6.04 billion. Eli Lilly And Co had a net margin of 1.85% and a return on equity of 42.84%. The company’s revenue for the quarter was up 7.1% compared to the same quarter last year. During the same quarter last year, the company earned $1.05 earnings per share. Equities research analysts expect that Eli Lilly And Co will post 5.58 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 10th. Shareholders of record on Thursday, November 15th will be paid a dividend of $0.5625 per share. This represents a $2.25 dividend on an annualized basis and a yield of 1.98%. The ex-dividend date of this dividend is Wednesday, November 14th. Eli Lilly And Co’s dividend payout ratio is 52.57%.

A number of institutional investors and hedge funds have recently made changes to their positions in LLY. Welch Group LLC bought a new position in shares of Eli Lilly And Co in the third quarter valued at approximately $123,000. Zions Bancorporation bought a new position in shares of Eli Lilly And Co in the third quarter valued at approximately $128,000. Mainstay Capital Management LLC ADV raised its stake in shares of Eli Lilly And Co by 98.0% in the third quarter. Mainstay Capital Management LLC ADV now owns 1,218 shares of the company’s stock valued at $131,000 after acquiring an additional 603 shares during the last quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new position in shares of Eli Lilly And Co in the second quarter valued at approximately $114,000. Finally, Fort L.P. bought a new position in shares of Eli Lilly And Co in the second quarter valued at approximately $121,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

A number of equities research analysts recently weighed in on LLY shares. TheStreet raised Eli Lilly And Co from a “c+” rating to a “b+” rating in a research report on Tuesday, November 6th. Wolfe Research started coverage on Eli Lilly And Co in a research report on Tuesday, October 23rd. They set a “market perform” rating and a $119.00 target price on the stock. BMO Capital Markets raised Eli Lilly And Co from a “market perform” rating to an “outperform” rating and lifted their target price for the stock from $107.00 to $130.00 in a research report on Thursday, October 4th. Societe Generale set a $106.00 target price on Eli Lilly And Co and gave the stock a “hold” rating in a research report on Wednesday, November 7th. Finally, Barclays lifted their target price on Eli Lilly And Co from $98.00 to $107.00 and gave the stock an “overweight” rating in a research report on Friday, September 7th. Nine analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $111.53.

ILLEGAL ACTIVITY WARNING: “Insider Selling: Eli Lilly And Co (LLY) Major Shareholder Sells 15,500 Shares of Stock” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2018/12/07/insider-selling-eli-lilly-and-co-lly-major-shareholder-sells-15500-shares-of-stock.html.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Further Reading: Buyback

Insider Buying and Selling by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply